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and hospitalisation in the exercise-trained patients (p=0.007 by logrank 
test). 
Conclusions: This meta-analysis suggests that exercise training signif- 
icantly reduces hospitalisations in HF patients by approximately a half, 
and may favourably influence survival. The number needed to treat to 
prevent one hospital±sat±on at two years was 13, and to prevent one death 
or hospital±sat±on was 12. 
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Statin therapy is associated with a 67% reduction in mortality in 
patients with sever chronic heart failure: Results from the placebo 
arm of the ENABLE study. 
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Recent small studies have demonstrated that statins therapy is correlated 
with improved outcome in patients with chronic heart failure. 
Methods: We examined the effect of  statin therapy on the outcome of 
1,000 patients with chronic CHF NYHA IIlb or IV and echocardiographic 
ejection fraction < 35% enrolled in the placebo arm of the ENABLE 
study. 
Statin therapy allocation was not randomized and decided by each in- 
vestigator, Statin therapy included simvastatin, atrovastatin, pravastati, 
lovastatin, cerivastatin and fluvastatin in different doses. 
Results: Statin treatment was related to a 67% reduction in the risk 
of all cause mortality (p<0.0001, Figure) but was not correlated with 
re-admisions due to heart failure. In the present cohort statin treatment 
was an the strongest predictor of  outcome and remained an independed 
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Conclusions: Although retrospective, the results of  the present study 
demonstrate a strong correlation between all cause mortality and statin 
treatment in patients with heart failure. This ovservation requires verifi- 
cation by a large prospective randomized study. 
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Background: The efficacy of selective aldosterone blockade with 
eplerenone (EPL) was demonstrated in EPHESUS, with mean reductions 
of 15% in total mortality and 13% in CV mortality/CV hospitalizations. 
EPL also reduced the number of patients hospitalized for heart failure 
(HF) by 15% and the number of episodes of HF hospitalizations by 23%. 
This retrospective analysis was undertaken to determine the mean length 
of stay (LOS) among patients who had at least one HF hospitalization 
during the study. 
Methods: Patients with post-myocardial infarction (AMI) HF and left 
ventricular ejection fraction (EF) less than or equal to 40% were random- 
ized 3 to 14 days after index AMI to EPL (25 mg titrated to 50 mg QD; 
n=3319) or placebo (PBO; n=3313) plus standard therapy and followed 
for up to 2.5 years (mean 16 months). Mean LOS for patients with at least 
one HI: admission was calculated between the two groups and differences 
were compared using the t-test. 
Results:  There were a total of  3308 (49.9%) patients with at least one 
hospitalization during the study, of which 831 patients (12.5%) had the 
hospitalization for HF (table). 
Region EPL EPL PBO PBO P 
(n=3319) (n=3319)  (n=3313)  (n=3313) value 
LOS # No. Pts (%) LOS e No. Pts (%) 
Overall 8.6 ± 8.8 390 (11.8) 10.3 ± 11.0 441 (13.3) 0.013 
US/Canada 7.7 ± 9.0 62 10.0 5:12.2 92 
Western Europe 8.4 ± 8.0 i09 10.4 ± 9.8 119 
Eastern Europe 11.0 ± 10.5 129 12.1 4- 12.2 149 
Latin America 6.9 ± 7.0 46 8.7 ± 9.4 39 
Rest of World 5.3 ± 3.9 44 6.2 ± 6.0 42 
#Mean ± SD. 
Conclusion: Treatment with EPL significantly reduced HF hospitaliza- 
tion and LOS for post-AMI patients with HF, indicating a significant 
improvement in morbidity in this population. These results were consis- 
tent across the different countries. 
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Background: Disability (i.e. loss of ability to perform independently ac- 
tivities of daily living, ADL), cognitive impairment, depression and poor 
quality of  life (QoL) are common in frail heart failure (HF) elderly pts. 
However, little is known about the impact of  recommended treatments 
-such as Betablockers (BB) - on these conditions. As a consequence, BB 
are usually underprescribed because their perceived side effects. Aim of 
the study was to assess the influence of carvedilol treatment on the de- 
gree of disability, cognitive impairment, depressive symptoms and QoL 
in elderly pts using multimensional assessment instruments. 
Methods: A total of  1126 pts aged >70 yrs (76±5, range 70-93, 
Males 63%, NYHA III-IV 51.8%) from the observational multicentre 
study BRING-UP2 (Betablockers in patients with congestive heart fail- 
ure.Guided use in clinical practice-2) were evaluated. Data were collected 
at baseline and at 1-year follow-up using VAS questionnaire (eValuation 
of elderly pAtientS), including: socio-economic factors, ADL score (14- 
item scale), cognitive function (MMSE, WAIS Digit-Symbol: WDS), 
depressive symptoms (15-item GDS) and Quality of Life (Minnesota 
LHFQ). 
Results: At baseline visit, 375 pts (33%) were already on BB treatment 
and were excluded from the study, 317 (28.2%) started BB treatment 
(ST) and 434 (38.8%) were found not eligible to BB (NT), according to 
Guidelines recommendations. Except for gender (25.2% vs 41.7% males 
on ST vs NT pts, p<0.01), comorbidity (Charlson index >2  49% vs 
62%, p=0.0029) no baseline significant differences were found between 
the 2 groups in socio-economic variables, depressive symptoms (GDS 
>6 46.5% vs 47.0% (p--ns), disability (ADL sco re< l l  42.5% vs 42.6% 
